ISAM Webinar: In-Vitro Testing Strategies for Nasal Drug Products
ISAM is pleased to announce the next Webinar presented by Clair Brooks, Applications Specialist at Copley Scientific, Nottingham, England, UK. She will explore the latest advancements in nasal drug delivery, focusing on in-vitro testing methods and innovative tools for improved nasal deposition.Key points:• Utilising the intranasal route for systemic and nose-to brain drug delivery • Compendial in vitro testing requirements of nasal drug products • Challenges and developments in nasal testing• Studying nasal deposition with the Alberta Idealised Nasal Inlet and the Kiel Nasal InletNasal drug delivery presents a promising avenue for therapeutic administration, offering a non-invasive route that bypasses the gastrointestinal tract and hepatic first-pass metabolism. This method has become increasingly attractive for systemic drug administration, particularly for drugs that are poorly absorbed orally, as it utilises the highly vascularised and large surface area of the nasal mucosa for rapid absorption. Additionally, the permeability of the nasal mucosa and its nerve pathways are being utilised to achieve targeted drug delivery to the brain, effectively overcoming the blood-brain barrier. Rigorous testing is vital to ensure the safety, efficacy and quality of these products, and compendial in-vitro testing methods play a key role in evaluating product performance and ensuring compliance with regulatory standards. However, challenges remain in replicating physiological conditions and addressing patient-to-patient variability. Ongoing research and technological advancements continue to drive progress in this area, including the development of realistic nasal models to improve in vitro-in vivo correlations and automated device actuation to standardise dose delivery when evaluating bioequivalence. This webinar explores the advancements in in-vitro nasal testing and presents recent studies using two novel tools to look at nasal deposition.
